Myrexis, Inc., headquartered in New York, New York, is in the process of evaluating strategic alternatives, including focusing on identifying, evaluating and making financial investments in life sciences assets. In February 2012, the Company announced that it was shifting its strategic direction and suspended development activities of all its preclinical and clinical development programs in oncology and autoimmune diseases.
Chief Executive Officer and Chief Financial Officer
Jonathan Couchman was appointed President, Chief Executive Officer and Director of Myrexis, Inc. on January 22, 2013. Mr. Couchman was appointed Chief Financial Officer of Myrexis, Inc. on March 1, 2013. Mr. Couchman also has served as President, Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Xstelos Holdings, Inc. since January 23, 2012. Prior to that, Mr. Couchman served as Chairman of the Board, Member of the Compensation Committee and Chairman of the Governance Committee of Footstar Inc. from March 2006 to May 2012 and Chief Executive Officer and Chief Financial Officer from January 2009 to May 2012. Mr. Couchman served as a board member of Pernix Therapeutics Holdings, Inc. (f/k/a Golf Trust America) from December 2007 to March 2010. Prior to that time he was a private investor and investment manager. Mr. Couchman received a B.S. in Finance from California State University, Chico, California.